Initiating Growth Hormone Therapy in Pediatric Patients

The panel moves into Section 2 of the series, focused on GHD treatment across the lifespan. This episode examines when and how to initiate GH therapy, how treatment goals guide management, and the emerging role of long-acting weekly formulations.

Dr. Alter explains that in pediatric patients, the decision to start GH therapy is a shared one involving the clinician and family — with one exception: neonates with hypoglycemia and microphallus require prompt treatment, sometimes with twice-daily dosing. In all other cases, family values, compliance capacity, and disease severity shape the final decision.

Regarding formulation choice, Dr. Alter describes his evolving confidence in long-acting (weekly) GH analogs. Earlier hesitancy has given way to extensive positive clinical experience with three approved weekly products: lonapegsomatropin, somapacitan, and somatrogon. A compelling case of a pan-hypopituitary child with septo-optic dysplasia who thrived only after switching from daily to weekly GH illustrates the transformative adherence benefits of long-acting formulations.

Dr. Alter discusses IGF-1 monitoring on daily GH, aiming for 0 to +2 standard deviations. On weekly formulations, IGF-1 measurement timing matters — ideally around day 3–4 post-injection — and clinicians must account for injection day when interpreting results.

For adult patients, Dr. Agrawal outlines a weight-independent, age-stratified dosing approach. Adults aged 30–60 typically start at 0.3–0.4 mg/day; those over 60 start at 0.1–0.2 mg/day. A critical adult-specific factor is oral estrogen use — which causes GH resistance at the hepatic level and may necessitate dose doubling. Transdermal estrogen does not carry this effect.

In the next episode, “Initiating and Managing Growth Hormone Therapy in Adults,” the panel examines how adult GH therapy is titrated, what treatment success looks like, and when to question or discontinue therapy.